Trial Profile
A double-blind, multicenter, placebo controlled, acute and extension study of 2 doses of MK-0869 [aprepitant] in the treatment of patients with major depressive disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Oct 2005 New trial record.